These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2122025)

  • 21. Interference of oral phenytoin absorption by continuous nasogastric feedings.
    Bauer LA
    Neurology; 1982 May; 32(5):570-2. PubMed ID: 6803191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of nasogastric phenytoin and enteral feeding solution.
    Weinryb J; Cogen R
    J Am Geriatr Soc; 1989 Feb; 37(2):195-6. PubMed ID: 2492043
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro evaluation of nasogastric administration methods for phenytoin.
    Cacek AT; DeVito JM; Koonce JR
    Am J Hosp Pharm; 1986 Mar; 43(3):689-92. PubMed ID: 3706323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of a practical pH cutoff level for reliable confirmation of nasogastric tube placement.
    Gilbertson HR; Rogers EJ; Ukoumunne OC
    JPEN J Parenter Enteral Nutr; 2011 Jul; 35(4):540-4. PubMed ID: 21622643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenytoin-enteral feeding interaction.
    Haley CJ; Nelson J
    DICP; 1989 Oct; 23(10):796-8. PubMed ID: 2510408
    [No Abstract]   [Full Text] [Related]  

  • 26. Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding.
    Kitchen D; Smith D
    Seizure; 2001 Jun; 10(4):265-8. PubMed ID: 11466022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recovery of phenytoin from an enteral nutrient formula.
    Hooks MA; Longe RL; Taylor AT; Francisco GE
    Am J Hosp Pharm; 1986 Mar; 43(3):685-8. PubMed ID: 3085485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Causes of non-medication-induced nasogastric tube occlusion.
    Hofstetter J; Allen LV
    Am J Hosp Pharm; 1992 Mar; 49(3):603-7. PubMed ID: 1598935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to minimize interaction between phenytoin and enteral feedings: two approaches.
    Gilbert S; Hatton J; Magnuson B
    Nutr Clin Pract; 1996 Feb; 11(1):28-31. PubMed ID: 8700059
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug-nutrient interactions in enteral feeding: a primary care focus.
    Varella L; Jones E; Meguid MM
    Nurse Pract; 1997 Jun; 22(6):98-104. PubMed ID: 9211455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the phenytoin-enteral feeding formula interaction a myth?
    Bertino JS
    Nutr Clin Pract; 1996 Aug; 11(4):175-6. PubMed ID: 9070019
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of enteral tube feeding on serum phenytoin levels.
    Ozuna J; Friel P
    J Neurosurg Nurs; 1984 Dec; 16(6):289-91. PubMed ID: 6438282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comment: phenytoin and enteral feedings.
    Fitzsimmons WE; Garnett WR; Krueger KA
    Drug Intell Clin Pharm; 1988 Nov; 22(11):920. PubMed ID: 3148456
    [No Abstract]   [Full Text] [Related]  

  • 34. Nasogastric and nasoenteric feeding tubes.
    Levy H
    Gastrointest Endosc Clin N Am; 1998 Jul; 8(3):529-49. PubMed ID: 9654567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Interaction of Phenytoin with Enteral Formulas, Proteins, and Dietary Fiber in Vitro and in Vivo].
    Kuwabara N; Ohta-Shimizu M; Fuwa F; Tsugita M; Sato N; Sato S; Nakagawa S
    Yakugaku Zasshi; 2023; 143(1):85-94. PubMed ID: 36596543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of carbamazepine suspension through nasogastric feeding tubes.
    Clark-Schmidt AL; Garnett WR; Lowe DR; Karnes HT
    Am J Hosp Pharm; 1990 Sep; 47(9):2034-7. PubMed ID: 2121028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimizing respiratory complications of nasoenteric tube feedings: state of the science.
    Metheny N
    Heart Lung; 1993; 22(3):213-23. PubMed ID: 8491657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic locking of enteral feeding tubes with pancreatic enzymes.
    Sriram K; Jayanthi V; Lakshmi RG; George VS
    JPEN J Parenter Enteral Nutr; 1997; 21(6):353-6. PubMed ID: 9406135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations of drug therapy in patients receiving enteral nutrition.
    Gora ML; Tschampel MM; Visconti JA
    Nutr Clin Pract; 1989 Jun; 4(3):105-10. PubMed ID: 2499752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compatibility of oral morphine sulfate solution with enteral feeding products.
    Udeani GO; Bass J; Johnston TP
    Ann Pharmacother; 1994 Apr; 28(4):451-5. PubMed ID: 8038464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.